Shenzhen Hepalink (09989) Announces January 2026 Share Capital and Public Float Update

Bulletin Express

Feb 03

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (stock code: 09989) reported its monthly return for the period ended 31 January 2026. The total authorised and registered share capital remained at RMB 1,467,296,204. This consists of 220,094,500 H shares (RMB 1 par value) and 1,247,201,704 A shares (RMB 1 par value), with no changes from the previous month.

The issued H share capital stood at 220,094,500 shares, while the issued A share capital totaled 1,247,201,704 shares, both unchanged. The company confirmed compliance with the public float requirements for H shares, noting that 5% of the total number of issued H shares (excluding treasury shares) is the applicable threshold.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1163421113"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163421113\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163421113?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 17:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163421113","market":"us","top_or_hot":-1,"title":"Shenzhen Hepalink (09989) Announces January 2026 Share Capital and Public Float Update","media":"Bulletin Express","content":"<p>Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (stock code: 09989) reported its monthly return for the period ended 31 January 2026. The total authorised and registered share capital remained at RMB 1,467,296,204. This consists of 220,094,500 H shares (RMB 1 par value) and 1,247,201,704 A shares (RMB 1 par value), with no changes from the previous month.</p>\n<p>The issued H share capital stood at 220,094,500 shares, while the issued A share capital totaled 1,247,201,704 shares, both unchanged. The company confirmed compliance with the public float requirements for H shares, noting that 5% of the total number of issued H shares (excluding treasury shares) is the applicable threshold.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shenzhen Hepalink (09989) Announces January 2026 Share Capital and Public Float Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShenzhen Hepalink (09989) Announces January 2026 Share Capital and Public Float Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-03 17:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (stock code: 09989) reported its monthly return for the period ended 31 January 2026. The total authorised and registered share capital remained at RMB 1,467,296,204. This consists of 220,094,500 H shares (RMB 1 par value) and 1,247,201,704 A shares (RMB 1 par value), with no changes from the previous month.</p>\n<p>The issued H share capital stood at 220,094,500 shares, while the issued A share capital totaled 1,247,201,704 shares, both unchanged. The company confirmed compliance with the public float requirements for H shares, noting that 5% of the total number of issued H shares (excluding treasury shares) is the applicable threshold.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09989","symbol_name":"海普瑞","start_time":0,"source_url":"","article_id":"1163421113","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163421113","pubTimestamp":1770109898,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (stock code: 09989) reported its monthly return for the period ended 31 January 2026. The total authorised and registered share capital remained at...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09989":"海普瑞"},"translate_title":"深圳海普瑞(09989)公布2026年1月股本及公众持股量更新","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09989":1},"content_text":"Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (stock code: 09989) reported its monthly return for the period ended 31 January 2026. The total authorised and registered share capital remained at RMB 1,467,296,204. This consists of 220,094,500 H shares (RMB 1 par value) and 1,247,201,704 A shares (RMB 1 par value), with no changes from the previous month.\nThe issued H share capital stood at 220,094,500 shares, while the issued A share capital totaled 1,247,201,704 shares, both unchanged. The company confirmed compliance with the public float requirements for H shares, noting that 5% of the total number of issued H shares (excluding treasury shares) is the applicable threshold.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}